Product Information

RYTARY ER 61.25 MG-245 MG CAP is a brand product labeled by Amneal Pharmaceuticals LLC, priced at $4.9962 per EA under NDC 64896066401. Its NADAC has been published 549 times since Feb 17, 2016.

FDA first approved this application on Jan 7, 2015.

The High Outlier badge above means this manufacturer's average price in the Carbidopa and Levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

RYTARY ER 61.25 MG-245 MG CAP

Carbidopa and Levodopa
$4.9962per EA
High Outlier

Strength

61.25; 245 mg/1; mg/1

NDC

64896066401

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

CARBIDOPA HYDRATE; LEVODOPA

Approval Type

New Drug (NDA)

FDA Application

NDA203312

FDA Approved

1/7/2015

On Market Since

1/12/2015

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid

Price Statistics

The NADAC for RYTARY ER 61.25 MG-245 MG CAP has been published 549 times since Feb 17, 2016, and over the history we have for it it has risen 78.9%. The table below summarizes its recorded NADAC range and movement.

Current price$4.9962 per EA
All-time high$5.0118 (Apr 16, 2025)
All-time low$2.7924 (Feb 17, 2016)
52-week high$5.0003
52-week low$4.9916
Median price$4.2009
Average price$4.1637
Largest weekly change+9.9% (Feb 9, 2022)
Weeks tracked549
Tracking sinceFeb 17, 2016

Price History

1W

+0.0%

1M

+0.0%

3M

+0.0%

6M

+0.1%

1Y

-0.1%

3Y

+0.3%

5Y

+18.9%

All

+78.9%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 30% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of RYTARY ER 61.25 MG-245 MG CAP?

The current National Average Drug Acquisition Cost (NADAC) for RYTARY ER 61.25 MG-245 MG CAP, manufactured by Amneal Pharmaceuticals LLC, is $4.9962 per EA (NDC 64896066401), effective Aug 19, 2026.

How has the price of RYTARY ER 61.25 MG-245 MG CAP changed over time?

Over the history we have for it, the NADAC for RYTARY ER 61.25 MG-245 MG CAP has risen 78.9%. It has been tracked across 549 weekly CMS publications since Feb 17, 2016.

What are the highest and lowest recorded NADAC prices for RYTARY ER 61.25 MG-245 MG CAP?

Since Feb 17, 2016, the NADAC for RYTARY ER 61.25 MG-245 MG CAP has ranged from a low of $2.7924 (Feb 17, 2016) to a high of $5.0118 (Apr 16, 2025), with a median of $4.2009 per EA.

Are there cheaper alternatives to RYTARY ER 61.25 MG-245 MG CAP?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RYTARY ER 61.25 MG-245 MG CAP, is $3.5009 per EA — about 30% below RYTARY ER 61.25 MG-245 MG CAP.

Who manufactures RYTARY ER 61.25 MG-245 MG CAP?

RYTARY ER 61.25 MG-245 MG CAP (NDC 64896066401) is labeled by Amneal Pharmaceuticals LLC, and CMS classifies it as a brand product.